Related Experiment Video
Updated: Jul 6, 2026

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
Use of dronabinol for cannabis dependence: two case reports and review
Frances R Levin1, Herbert D Kleber
1Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA. frl2@columbia.edu
Abstract:
Marijuana is the most commonly used illicit drug in the United States and throughout the world. Despite this, the number of laboratory studies that have assessed pharmacologic agents to target cannabis withdrawal symptoms or reduce the reinforcing effects of marijuana has been modest. Unlike alcohol, cocaine, opiates, or nicotine, there has been a minimal number of clinical pharmacologic treatment trials that have targeted marijuana use. Based on recent laboratory studies, dronabinol (delta-9-tetrahydrocannabinol) has been shown to reduce cannabis withdrawal symptoms and the subjective effects of marijuana. Given that agonist agents have been found to be effective for opiate and nicotine dependence, the clinical utility of dronabinol for cannabis dependence is a reasonable approach. Two case reports using dronabinol are presented. The potential benefit, as well as questions that arise from the use of this medication in cannabis-abusing populations, is presented. Also, future areas of research that might be explored are discussed.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Dependence
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS Depressants: Alcohol and Nicotine
Drug Regulation

